Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naproxcinod Efficacy and Safety in Knee Osteoarthritis
NCT00542555Phase 3Completed
- Sponsor
- Nicox S.A.
- Start
- Dec 2005
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of naproxcinod in knee osteoarthritis (OA) (4 arms), sponsored by Nicox S.A. Primary endpoint: Relief of Osteoarthritis Signs and Symptoms. Started Dec 2005; status: completed.
02
Drugs
naproxcinod
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT00542555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00542555.